Methocarbamol

Selected oral tablets and IV/IM injection are adjuncts to rest, physical therapy and other measures for discomfort with acute painful musculoskeletal conditions. Atmeksi explicitly indicates this use at age ≥ 16; tablet pediatric safety/effectiveness below 16 is not established. Neither oral form is labeled as long-term treatment of neurologic spasticity.

The injection label includes specialized adjunctive tetanus directions and a pediatric exception for tetanus. It does not replace wound care, antitoxin, antimicrobial, airway or other supportive treatment. These label directions are not a complete contemporary tetanus-care protocol or permission to use high-dose tetanus regimens for ordinary muscle pain.

Adult tablet regimens and Atmeksi age ≥ 16 regimens are summarized below; assess sedation and individual need.

Selected injection 100 mg/mL: moderate symptoms may need a single 1 g dose; severe/postoperative cases unable to take oral therapy may repeat 1 g every 8 hours, maximum 3 g/day for ≤ 3 consecutive days except tetanus. If symptoms persist, label permits repeating after a 48-hour drug-free interval. Transition to oral when feasible. IV rate ≤ 3 mL/min (300 mg/min); may give undiluted or dilute one 1 g vial in no more than 250 mL isotonic saline or D5W. Avoid extravasation; keep recumbent during and for 10–15 minutes after IV administration. IM: no more than 5 mL per gluteal site; not recommended SC. Do not refrigerate diluted infusion.

Adult initial label regimen: 1–2 vials into established IV tubing, with additional drug in infusion to total up to 3 g initially; repeat every 6 hours until nasogastric administration is possible. Label mentions oral totals up to 24 g/day only in this specialized context. The pediatric tetanus exception has separate specialist dosing directions in the linked label. No pediatric tetanus algorithm is reproduced here: the primary label’s 1.8 g/m² limit lacks an explicit per-day qualifier, so it must not be inferred as a safe dosing schedule from this summary.

Oral labels provide no validated fixed renal/hepatic adjustment: clearance is lower in dialysis patients and cirrhosis, so individualize cautiously and monitor sedation. Injection is contraindicated with known or suspected renal pathology due to polyethylene glycol 300. Acute-use indication supports reassessing need and reducing initial dose; no universal oral 2–3-week duration or taper is specified in these labels.

Hypersensitivity to methocarbamol or ingredients of the selected formulation. Injection adds known or suspected renal pathology because of polyethylene glycol 300. That vehicle contraindication is not stated as an oral-form contraindication; oral organ impairment still needs individualized review.

The three selected current U.S. labels have no boxed warning. CNS depression, injection renal restrictions, seizure precautions and hypersensitivity remain clinically significant.

Reported effects include sedation, dizziness, confusion, blurred/double vision, headache, incoordination, nausea/dyspepsia, hypotension/bradycardia/syncope, rash and rare serious allergy, seizures, jaundice or leukopenia; injection adds pain/sloughing and thrombophlebitis. Reliable incidence is not established for many reported events. Overdose can cause respiratory/CNS depression, hypotension, seizures, coma and death, including with other sedatives. Obtain urgent medical/Poison Help advice (U.S. 1-800-222-1222); support airway/vitals. Atmeksi advises generally avoiding GI decontamination/emesis due to aspiration risk; extracorporeal removal has no proven benefit.

Selected tablet/injection warnings describe reported fetal/congenital abnormalities, inadequate reproductive evidence and use only when clearly needed/benefit outweighs hazards, particularly early pregnancy. Atmeksi’s March 2026 risk summary says limited decades-of-use case reports have not identified increased major-birth-defect, miscarriage or other adverse-outcome risk; this does not prove safety or erase other labels’ warnings. Human milk/infant data are absent; animal milk transfer occurs. Discuss maternal need, breastfeeding benefits and potential infant effects rather than assuming no exposure.

Atmeksi is indicated at age ≥ 16; oral tablet/suspension safety/effectiveness below 16 is not established. Injection pediatric safety/effectiveness is established only as the label’s tetanus exception; no other pediatric regimen is supplied. Older volunteers had slightly longer half-life and reduced protein binding; individualize cautiously with sedation/falls, renal/hepatic function and concomitant sedatives.

Small studied dialysis cohort had ~40% reduced clearance; alcoholic-cirrhosis cohort had ~70% reduced clearance and longer half-life. These findings are not percentage dose-reduction instructions. Oral therapy has no fixed adjustment algorithm; injection’s renal-pathology contraindication is vehicle-specific. Evaluate cumulative sedative effects and tolerability.

The human mechanism is not established; generalized CNS depression/sedation may explain benefit. No direct effect on the striated-muscle contractile apparatus, motor endplate or nerve fiber is established.

Binding / half-life

~46–50% protein bound; healthy-volunteer elimination half-life ~1–2 hours, longer in studied cirrhosis.

Metabolism / elimination

Dealkylation/hydroxylation and likely conjugation; metabolites mainly urine, with small unchanged-drug amounts.

Atmeksi absorption

Median peak ~0.66 hours fasting; food lowers Cmax/AUC and delays peak (~1.6 hours). Its dosing section does not prescribe a universal food requirement.

Organ effects

Reduced clearance in renal/hepatic cohorts supports individual assessment; short half-life is not permission to exceed prescribed dosing.

Monitor acute symptom relief and function, alertness, dizziness, coordination, blood pressure/fainting, allergy and need for continued therapy. Review organ impairment, alcohol and sedative co-therapy. Observe myasthenia patients for weakness. With injection, supervise rate/site/vitals and seizure risk; urinary output and airway need attention in overdose.

Use the prescribed form/dose; shake Atmeksi at least 30 seconds and measure the prescribed volume accurately. Avoid alcohol and driving/hazardous tasks until effects are known. Discuss all sedatives, pregnancy and breastfeeding. Seek urgent care for airway swelling, severe weakness, seizure, inability to wake or breathing impairment. No unsourced universal missed-dose or taper algorithm is provided; ask the dispensing clinician for individualized instructions.

Granules 500 mg tablet: light orange, round film-coated, G above score / 500; example 100-tablet bottle NDC 70010-754-01. Exact generic appearance differs by manufacturer.

Selected tablets: 20–25°C in tight container. Atmeksi: 20–25°C, keep out of reach/sight of children. Baxter injection: 20–25°C, excursions 15–30°C; discard unused single-dose remainder. Diluted infusion must not be refrigerated. Keep all products securely away from children.